^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Microbiome modulator

    Related drugs:
    8d
    MET4-IO: Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy Patients (clinicaltrials.gov)
    P2/3, N=65, Active, not recruiting, University Health Network, Toronto | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    19d
    R-3750-01-LU: A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Rise Therapeutics LLC | Trial completion date: Dec 2027 --> Dec 2028 | Initiation date: Nov 2025 --> Sep 2026 | Trial primary completion date: Apr 2027 --> Apr 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    19d
    R-3750 in Patients With Mild to Moderate Ulcerative Colitis (clinicaltrials.gov)
    P1, N=36, Recruiting, Rise Therapeutics LLC | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Sep 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    20d
    ROAR: REBYOTA™ Prospective Registry (clinicaltrials.gov)
    P=N/A, N=145, Completed, Ferring Pharmaceuticals | Recruiting --> Completed | Trial completion date: Apr 2026 --> Aug 2025 | Trial primary completion date: Feb 2026 --> Aug 2025
    Trial completion • Trial completion date • Trial primary completion date
    1m
    A Phase 1b Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Multiple Dose Safety and Tolerability Study of Daily Dosing of BL-001 for 12 Weeks in Adults with Obesity (ACTRN12626000061336)
    P1, N=48, Not yet recruiting, Bloom Science Australia Pty Ltd
    New P1 trial
    2ms
    StarFish-UC: Confirmatory Clinical Study in Active Ulcerative Colitis (clinicaltrials.gov)
    P2, N=204, Not yet recruiting, MRM Health NV
    New P2 trial
    2ms
    Pembrolizumab and EDP1503 in Advanced Melanoma (clinicaltrials.gov)
    P2, N=8, Terminated, University of Chicago | Trial completion date: Nov 2027 --> Jul 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2027 --> Jul 2025; Drug supply no longer available.
    Trial completion date • Trial termination • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • EDP1503
    3ms
    adored: Allergic Disease Onset Prevention Study (clinicaltrials.gov)
    P1/2, N=283, Completed, Siolta Therapeutics, Inc. | Active, not recruiting --> Completed
    Trial completion
    4ms
    A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC (clinicaltrials.gov)
    P2, N=87, Recruiting, LISCure Biosciences | Not yet recruiting --> Recruiting | Initiation date: Mar 2025 --> Nov 2025
    Enrollment open • Trial initiation date
    4ms
    Medicinal Cannabis for Endometriosis: The Gut Microbiome (ACTRN12624000828527)
    P2, N=28, Not yet recruiting, Western Sydney University | N=42 --> 28
    Enrollment change
    5ms
    KAN-004 for Immune-Related Diarrhea or Colitis (clinicaltrials.gov)
    P1, N=21, Not yet recruiting, Centre hospitalier de l'Université de Montréal (CHUM)
    New P1 trial
    5ms
    Microbiome-Modulating Prophylaxis RCT: Antibiotic vs Gynoflor in Postmenopausal Women With Recurrent Cystitis (clinicaltrials.gov)
    P4, N=100, Recruiting, Mahidol University
    New P4 trial